Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity

Area of Science:

• Otolaryngology
• Pharmacology
• Toxicology

Background:

• Aminoglycoside antibiotics, like gentamicin, are effective and affordable but pose a significant risk of ototoxicity, leading to sensorineural hearing loss.
• The ototoxic mechanism of aminoglycosides is linked to the production of nitric oxide (NO).
• Investigating NO inhibitors could offer a strategy for preventing aminoglycoside-induced hearing damage.

Purpose of the Study:

• To evaluate the otoprotective potential of nitro-L-arginine methyl ester (L-NAME), a nitric oxide (NO) inhibitor, against gentamicin-induced hearing loss.
• To determine if L-NAME can prevent or mitigate sensorineural hearing loss caused by aminoglycoside antibiotics.

Main Methods:

• An experimental study involving 30 Sprague-Dawley rats.
• Gentamicin was administered to the middle ear of 27 rats.
• The NO inhibitor L-NAME was topically applied to 12 of the gentamicin-exposed rats.
• Hearing loss was assessed by measuring shifts in auditory brainstem response thresholds.

Main Results:

• L-NAME significantly reduced gentamicin-induced hearing loss specifically in the high-frequency range.
• No significant protective effect of L-NAME was observed in the middle or low-frequency ranges.
• The findings suggest a frequency-dependent otoprotective role for L-NAME against aminoglycoside toxicity.

Conclusions:

• Nitro-L-arginine methyl ester (L-NAME) demonstrates partial otoprotection against high-frequency hearing loss induced by gentamicin.
• The study highlights the role of nitric oxide in aminoglycoside ototoxicity and suggests targeted NO inhibition may be beneficial for specific frequencies.
• Further investigation is warranted to fully elucidate the therapeutic potential and mechanisms of L-NAME in preventing aminoglycoside-induced ototoxicity.